Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10
Capricor Therapeutics (NASDAQ: CAPR) will announce its first quarter 2022 financial results on May 10, 2022, followed by a conference call at 4:30 p.m. ET. The company focuses on developing cell and exosome-based therapeutics for various diseases, with its lead candidate, CAP-1002, aimed at treating Duchenne muscular dystrophy. The call will discuss recent corporate updates and financial performance. A replay will be available post-broadcast. Investors can access the call via a toll-free number or a webcast link.
- Company focuses on transformative therapies including cell and exosome-based therapeutics.
- Lead candidate CAP-1002 in clinical development for Duchenne muscular dystrophy.
- None.
Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the first quarter ended March 31, 2022, after the market close on Tuesday, May 10, 2022. Management will then host a webcast and conference call at 4:30 p.m. ET on May 10.
| Title: | Capricor Therapeutics First Quarter 2022 Financial Results and Recent Corporate Update Conference Call and Webcast | |
| Date: | Tuesday, May 10, 2022 | |
| Time: | 4:30 p.m. ET | |
| Conference Call Details: | Toll-Free: 888-256-1007 International: 929-477-0448 Conference ID: 3332017 | |
| Webcast: | Webcast Link - Click Here | |
The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on developing transformative cell and exosome-based therapeutics and vaccines for treating and preventing a broad spectrum of diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in clinical development for treating Duchenne muscular dystrophy. Capricor is also developing its exosome technology as a next-generation therapeutic platform. The Company’s current focus is on developing exosomes capable of delivering nucleic acids, including mRNA as well as proteins, to treat or prevent a variety of diseases. For more information, visit www.capricor.com, and follow the Company on Facebook, Instagram and Twitter.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on March 11, 2022. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.
For more information, please contact:
Capricor Media Contact :
Raquel Cona
KCSA Strategic Communications
rcona@kcsa.com
212.896.1204
Capricor Investor Contact :
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
617.435.6602
Capricor Company Contact :
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
310.358.3200
FAQ
When will Capricor Therapeutics release its Q1 2022 financial results?
What time is the Capricor Therapeutics conference call?
How can I access the Capricor Therapeutics webcast?
What is CAP-1002 developed by Capricor Therapeutics?
Is CAP-1002 approved for any indications?
